CN102356156A - 用于治疗神经退行性疾病或与细胞周期未预期激活相关疾病的包含编码cdk4/cdk6抑制子的诱导型基因的载体 - Google Patents

用于治疗神经退行性疾病或与细胞周期未预期激活相关疾病的包含编码cdk4/cdk6抑制子的诱导型基因的载体 Download PDF

Info

Publication number
CN102356156A
CN102356156A CN2010800127623A CN201080012762A CN102356156A CN 102356156 A CN102356156 A CN 102356156A CN 2010800127623 A CN2010800127623 A CN 2010800127623A CN 201080012762 A CN201080012762 A CN 201080012762A CN 102356156 A CN102356156 A CN 102356156A
Authority
CN
China
Prior art keywords
vector
expression
cell
cdk4
cdk6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800127623A
Other languages
English (en)
Chinese (zh)
Inventor
T·阿伦特
U·于贝罕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Leipzig
Original Assignee
Universitaet Leipzig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Leipzig filed Critical Universitaet Leipzig
Publication of CN102356156A publication Critical patent/CN102356156A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800127623A 2009-02-04 2010-02-04 用于治疗神经退行性疾病或与细胞周期未预期激活相关疾病的包含编码cdk4/cdk6抑制子的诱导型基因的载体 Pending CN102356156A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001521A EP2218784A1 (en) 2009-02-04 2009-02-04 Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders
EP09001521.5 2009-02-04
PCT/EP2010/000702 WO2010089122A2 (en) 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle

Publications (1)

Publication Number Publication Date
CN102356156A true CN102356156A (zh) 2012-02-15

Family

ID=40673417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800127623A Pending CN102356156A (zh) 2009-02-04 2010-02-04 用于治疗神经退行性疾病或与细胞周期未预期激活相关疾病的包含编码cdk4/cdk6抑制子的诱导型基因的载体

Country Status (8)

Country Link
US (2) US20120004277A1 (https=)
EP (2) EP2620447B1 (https=)
JP (1) JP5869884B2 (https=)
KR (1) KR101378353B1 (https=)
CN (1) CN102356156A (https=)
AU (1) AU2010211289B2 (https=)
CA (1) CA2751531A1 (https=)
WO (1) WO2010089122A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108319816A (zh) * 2018-02-27 2018-07-24 温州大学 一种基于基因通路识别小分子核糖核酸的方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653324B2 (en) * 2010-06-11 2014-02-18 Fox Chase Cancer Center TetO-p16 transgenic mice
WO2012050975A2 (en) * 2010-09-29 2012-04-19 The University Of North Carolina At Chapel Hill Novel circular mammalian rna molecules and uses thereof
KR101255338B1 (ko) * 2010-12-15 2013-04-16 포항공과대학교 산학협력단 표적 세포에 대한 폴리뉴클레오티드 전달체
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
AU2015311704B2 (en) * 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936034C1 (de) * 1999-07-30 2001-01-25 Univ Leipzig Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033277A2 (en) * 2003-09-29 2005-04-14 University Of Rochester Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
JP4956427B2 (ja) * 2004-07-21 2012-06-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
EP1838841A2 (en) * 2004-12-23 2007-10-03 The Ludwig Institute for Cancer Research Engineered dopamine neurons and uses thereof
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics
US9394538B2 (en) * 2008-05-07 2016-07-19 Shi-Lung Lin Development of universal cancer drugs and vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936034C1 (de) * 1999-07-30 2001-01-25 Univ Leipzig Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DAVID GOUKASSIAN 等: "Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis", 《FASEB JOURNAL》 *
DAVID S. PARK 等: "Cyclin Dependent Kinase Inhibitors and Dominant Negative Cyclin Dependent Kinase 4 and 6 Promote Survival of NGF-Deprived Sympathetic Neurons", 《THE JOURNAL OF NEUROSCIENCE》 *
FABIO M.V. ROSSI 等: "Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16", 《NATURE GENETICS》 *
IGOR MATUSHANSKY 等: "Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1", 《PNAS》 *
LENE UHRBOM 等: "Induction of senescence in human malignant glioma cells by p16INK4A", 《ONCOGENE》 *
ONNO KRANENBURG 等: "Cyclin Dl is an essential mediator of apoptotic neuronal cell death", 《THE EMBO JOURNAL》 *
TAKAYUKI MITSUHASHI 等: "Overexpression of p27Kip1 lengthens the G1 phase in a mouse model that targets inducible gene expression to central nervous system progenitor cells", 《PNAS》 *
UEBERHAM U 等: "expression of p16INK4a protein protects differentiated cells from apoptosis", 《SOCITERY FOR NEUROSCIENCE ABSTRACTS》 *
XI CHEN 等: "Senescence-like changes induced by expression of P21Waf1/Cip1 in NIH3T3 cell line", 《CELL RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108319816A (zh) * 2018-02-27 2018-07-24 温州大学 一种基于基因通路识别小分子核糖核酸的方法
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法

Also Published As

Publication number Publication date
WO2010089122A2 (en) 2010-08-12
EP2620447B1 (en) 2015-09-09
KR101378353B1 (ko) 2014-04-10
WO2010089122A3 (en) 2010-12-09
JP5869884B2 (ja) 2016-02-24
AU2010211289A1 (en) 2011-09-01
US20120004277A1 (en) 2012-01-05
KR20110121704A (ko) 2011-11-08
EP2620447A1 (en) 2013-07-31
JP2012516691A (ja) 2012-07-26
US20160144054A1 (en) 2016-05-26
CA2751531A1 (en) 2010-08-12
AU2010211289B2 (en) 2016-12-15
EP2218784A1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
JP5869884B2 (ja) 細胞周期の不定期の活性化に関連する神経変性障害または疾患の治療に有用なｃｄｋ４／ｃｄｋ６阻害剤をコードする誘導性遺伝子を含有するベクター
CA2580189C (en) Sirna-mediated gene silencing of alpha synuclein
US20250375466A1 (en) Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
Sapru et al. Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi
Theis et al. Lentiviral delivery of miR-133b improves functional recovery after spinal cord injury in mice
JP5894543B2 (ja) 神経筋疾患の治療のための修飾型Ｕ７ｓｎＲＮＡ
US12031135B2 (en) p63 inactivation for the treatment of heart failure
JP2019503205A (ja) 自己切断リボザイムのアプタマー媒介性制御を通じての遺伝子発現制御
Yun et al. Targeting upregulated RNA binding protein RCAN1. 1: a promising strategy for neuroprotection in acute ischemic stroke
Bertrand et al. Synthesis and studies on cell-penetrating peptides
CN103370414A (zh) 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法
Yang et al. Lentiviral‐Mediated RNA Interference against TGF‐Beta Receptor Type II in Renal Epithelial and Fibroblast Cell Populations In Vitro Demonstrates Regulated Renal Fibrogenesis That Is More Efficient than a Nonlentiviral Vector
Oh et al. Fluorescence imaging of huntingtin mRNA knockdown
CN117597151A (zh) 强直性肌肉营养不良1型治疗药
Wang et al. Lentivector-mediated RNAi efficiently downregulates expression of murine TNF-α gene in vitro and in vivo
Mastroyiannopoulos et al. Myotonic Dystrophy Type 1: Focus on the RNA Pathology and Therapy
US20090226446A1 (en) Method to Inhibit the Propagation of an Undesired Cell Population
Hung Combined gene therapy of siRNA and apoptosis inducing factor generated from a single transcriptional event
WO2004076667A1 (ja) サイクリンｂ遺伝子の発現抑制作用を有する二本鎖rnaオリゴヌクレオチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120215

RJ01 Rejection of invention patent application after publication